Your browser doesn't support javascript.
loading
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
Aoyama, Yosuke; Hoshino, Eri; Shimomura, Akihiko; Shimizu, Chikako; Taniyama, Tomoko; Tada, Manami; Yoshida, Nao; Sato, Hitomi; Nonogaki, Kiyomi; Yamamoto, Kazumasa; Yamanaka, Taro; Kizawa, Rika; Yamaguchi, Takeshi; Tanaka, Kiyo; Kobayashi, Yoko; Tamura, Nobuko; Tanabe, Yuko; Miura, Yuji; Kikawa, Yuichiro; Cho, Juhee; Kawabata, Hidetaka.
Afiliação
  • Aoyama Y; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan. yosuke.aoyama10@gmail.com.
  • Hoshino E; Division of Policy Evaluation, Department of Health Policy, Research Institute, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, Japan.
  • Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-Ku, Tokyo, Japan.
  • Shimizu C; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-Ku, Tokyo, Japan.
  • Taniyama T; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-Ku, Tokyo, Japan.
  • Tada M; Department of Breast Surgery, Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata-Shi, Osaka, Japan.
  • Yoshida N; Department of Breast Surgery, Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata-Shi, Osaka, Japan.
  • Sato H; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Nonogaki K; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Yamamoto K; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Yamanaka T; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Kizawa R; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Yamaguchi T; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Tanaka K; Department of Breast and Endocrine Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Kobayashi Y; Department of Breast and Endocrine Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Tamura N; Department of Breast and Endocrine Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Tanabe Y; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Miura Y; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
  • Kikawa Y; Department of Breast Surgery, Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata-Shi, Osaka, Japan.
  • Cho J; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Samsung Medical Center, 115 Irwon-Ro, Gangnam-Gu, Seoul, Republic of South Korea.
  • Kawabata H; Department of Breast and Endocrine Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Breast Cancer ; 31(2): 234-242, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38079066
BACKGROUND: The Chemotherapy-induced Alopecia Distress Scale (CADS) is a patient-reported outcome measure for assessing distress associated with Chemotherapy-induced alopecia (CIA). This study aimed to confirm the psychometric validity of the Japanese version of the CADS (CADS-J). METHODS: A total of 132 patients with breast cancer who developed CIA were asked to complete the CADS-J twice at 2 week intervals to confirm test-retest reliability. The body image domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) breast cancer-specific module, the self-esteem scale from the Rosenberg Self-Esteem Scale, and the emotional domain of the EORTC QLQ Core 30 were used to confirm the convergent validity of the CADS-J. The overall quality of life and physical domains of the EORTC QLQ Core 30 were used to confirm the discriminant validity of the CADS-J. RESULTS: In total, 125 participants provided valid responses. The mean age was 52.2 years. The overall Cronbach's alpha for the CADS-J was 0.903. The intraclass correlation coefficients of the first and second responses were r = 0.874, r = 0.952, r = 0.911, and r = 0.959 for the physical domain, emotional domain, activity domain, and relationship domain, respectively. In terms of convergent validity, the total CADS-J score was moderately correlated with body image (r = - 0.63), self-esteem (r = - 0.48), and the emotional domain (r = - 0.61). Regarding discriminant validity, the total CADS-J score was weakly correlated with the overall quality of life (r = - 0.34) and physical domain (r = - 0.24). CONCLUSIONS: The CADS-J is psychometrically reliable and valid for evaluating the distress caused by CIA. It is expected to be used in daily practice and as an endpoint in various studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antineoplásicos Limite: Female / Humans / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antineoplásicos Limite: Female / Humans / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article